Lonza maintains 2019 outlook after 'solid start' in Q1

Singapore

SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its speciality ingredients segment, the company said in a business update provided on Thursday.

The company described the first quarter of 2019 as a "solid start" to the year. For the first three months, Lonza's newly formed pharma biotech and nutrition segment came in ahead of expectations compared to the same period a year ago, while its speciality ingredients segment performed below expectations, with sales on the same level as in the first three months of 2018, Lonza noted.